![](/img/cover-not-exists.png)
131I-Tositumomab (Bexxar®)vs.90Y-Ibritumomab (Zevalin®) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma
Andrei Iagaru, Erik S. Mittra, Kristen Ganjoo, Susan J. Knox, Michael L. GorisVolume:
12
Language:
english
Pages:
6
DOI:
10.1007/s11307-009-0245-9
Date:
April, 2010
File:
PDF, 200 KB
english, 2010